The product is available in 50 countries.
Paragon Vision Sciences, a provider of orthokeratology, has entered the China market.
The Mesa, AZ-based firm announced the China Food and Drug Administration approval and commercial availability of its corneal reshaping/orthokeratology brand, Paragon CRT Contact Lenses, in the country.
Essilor China will serve as the exclusive distributor for the lenses in China. They will be widely available to ECPs within the next few months, according to a press release.
The non-surgical treatment option for managing myopia is now available in 50 countries, including the U.S.
“Various optical approaches to the control of myopia progression have been evaluated over the past few decades, and numerous studies have demonstrated that overnight cornea-reshaping contact lenses are both a safe and effective treatment for slowing and reducing the progression of myopia in children,” said Dr. Maria Liu, assistant professor of clinical optometry at the University of California, Berkeley, and founder and chief of UCB’s Myopia Control Clinic.
In China, one out of three people above the age of five suffers from myopia, according to the National Visual Health White paper released in June 2016 by the China Health Development Research Center at Peking University.
Richard Jeffries, president of Paragon Vision Sciences, said: “The practice of using overnight corneal reshaping with contact lenses to treat myopia is global and growing. With the availability of Paragon CRT Contact Lenses in China, eyecare practitioners have another evidence-based treatment option to help them treat myopia in children that may also contribute to preventing potential myopic-related ocular complications and vision loss from occurring later in life.”
Read more at Yahoo Finance.